Osimertinib plus cyclosporine for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding cyclosporine to the standard drug osimertinib can make it work better in people with advanced non-small cell lung cancer that has a specific EGFR gene change. You can join even if you haven't started treatment or have just started osimertinib within the last 3 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced non-small cell lung cancer with an EGFR gene change (either exon 19 deletion or L858R)
- You have not had chemotherapy for metastatic disease, or you have not started an EGFR-targeted pill, or you started osimertinib within the last 3 weeks
- You have at least one tumor that can be measured on scans and hasn't been treated with radiation
- You are generally able to care for yourself (ECOG 0–2)
- You are willing to use effective birth control if you or your partner can have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
Hear when a new Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.